2023 Costa Rica Tumor Markers Diagnostic Testing Market Assessment-Oncogenes, Biomarkers, GFs, CSFs, Hormones, Stains, Lymphokines-2022 Competitive Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

June 2023 | | ID: 2E2CCAB27BF2EN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

The report is available by section, and can be customized to specific information needs and budget.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

• Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contents

I. INTRODUCTION

II. MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

1. Introduction
2. Cancer Diagnostic Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Cancer Diagnostics
27. Oncogenes
  Abl/abl-bcr
  AIB1
  BCL-2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP-17
  Erb-B
  HPC1
  N-myc
  P40
  P51
  P53
  PIK3CA
  PTI-1
  Ras
  Reg
  Sis
  Src and others
28. Polypeptide Growth Factors
  Basic Fibroblast Growth Factor
  Beta-TGF
  Cachectin (TNT)
  Calmodulin
  ECFR
  Nerve Growth Factor (NGF)
  Epidermal Growth Factor (EGF)
  Ornithine Decarboxylase
  Transferrin
  Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
  Alpha-Interferon
  B Cell Growth Factors
  B Cell Growth Factor (BCGF)
  Gamma-Interferon
  Interleukin-1 (IL-1)
  Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Cancer Diagnostics
  N-Acetylglucosamine
  Actin
  Alpha-Actin
  Antineuronal Antibodies
  7B2
  B72.3
  Bax
  BCD-F9
  BLCA-4
  Blood Group Antigens A,B,H
  CA
  CA 72-4/TAG-72
  CA
  CA-242
  CA-549
  CAM
  CAR-3
  Cathepsin-D
  Chromogranin A and B
  Cluster 1 Antigen
  Cluster-5/5A Antigen
  CTA
  CU18
  DR-70
  DU-PAN-2
  Endometrial Bleeding Associated Factor
  Endostatin
  Epithelial Membrane Antigen
  Feulgen Hydrolysis
  Fibronectin
  FSH
  (1->3)-L-fucosyltransferase
  Gastrin-Releasing Peptide (GRP)
  GDCFP-15
  Glucagon
  Glycoamines
  H23
  Her-2
  Human Carcinoma Antigen
  HPA
  HSP27
  Intermediate Filaments
  Cytokeratins/CK18/Cyfra 21-1
  Desmin
  Gliofibrillary Acid Protein
  Neurofilaments
  Vimentin
  KA
  Kinases
  KP16D3
  LAI
  Leukocyte Common Antigen
  Lewis Antigens
  Lysophosphatidic Acid (LPA)
  Ma 695/Ma
  MABDF3
  MAG
  ME1
  Minactivin
  MN/CA9
  MSA
  Mucin Cancer Antigen (MCA)
  Multiple Tumor Suppressor
  Myosin
  NEA-130
  NMP22
  OA-519
  Opiod Peptides
  P-glycoprotein
  Pancreatic Oncofetal Antigen (POA)
  Placental Lactogen
  PR92
  Proliferative Index, Ki-67
  Px
  RB Inactivation/Deletion
  Ret
  SCCL
  Selectin
  Sialic Acid
  Sialyl SSEA-1/SLX
  SN10
  Somatostatin
  TA-90
  TABA
  Tachykinin
  TAG
  TPS
  Troponin
  Tubulin
  VCAM
  VEGF
  Villen and others

VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS

IX. CURRENT AND EMERGING TECHNOLOGIES

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies

X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

XI. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
  Abbott
  Affymetrix
  Beckman Coulter/Danaher/Cepheid
  Becton Dickinson
  bioMerieux
  Bio-Rad
  DiaSorin
  Eiken Chemical
  Elitech Group
  Enzo Biochem
  Fuifilm Wako
  Fujirebio
  Grifols
  Hologic
  Leica Biosystems
  PerkinElmer
  Qiagen
  QuidelOrtho
  Roche
  Siemens Healthineers
  Takara Bio
  Thermo Fisher and others